Fairmount Funds Management, Director: Zenas BioPharma ZBIO Buy · Filed 04/01

Trade details

Type: Insider buy
Amount: $3,000,000
Shares · price: 150,000 sh · $20.00 a share
Held after: 2,359,025 sh
Stock: Zenas BioPharma ZBIO
Person: Fairmount Funds ManagementDirector
Trade date: 26/03/31
Filed: 26/04/01
Days to filing: 1 days

First buy since 2023

Insiders buying this week: 6 insiders
Holding change: +6.8%

Zenas BioPharma trades, last 26 weeks

What else happened in Zenas BioPharma around then

Filed or reported within 30 days of the trade day · 03/01~04/30

Fairmount Funds Management's recent trades

Fairmount Funds ManagementDirector, 10% Stockholder
Planned saleOruka Therapeutics
Planned sale
Oruka Therapeutics
ORKA
$300M
3,553,410 sh
$300M
Filed 07/01
Traded 07/01
Fairmount Funds ManagementDirector
Planned saleSpyre Therapeutics
Planned sale
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
SellSpyre Therapeutics
Sell
Spyre Therapeutics
SYRE
$399.7M
4,684,781 sh
$399.7M
Filed 06/23
Traded 06/23
Fairmount Funds ManagementDirector
BuyViridian Therapeutics, Inc.\DE
Buy
Viridian Therapeutics, Inc.\DE
VRDN
$20M
1,176,470 sh
$20M
Filed 05/13
Traded 05/11
Fairmount Funds ManagementDirector
Planned saleCogent Biosciences
Planned sale
Cogent Biosciences
COGT
$242.6M
7,000,000 sh
$242.6M
Filed 03/31
Traded 03/31